Waters 将来の成長

Future 基準チェック /26

Waters利益と収益がそれぞれ年間8.6%と5.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に32.2% 10.3%なると予測されています。

主要情報

8.6%

収益成長率

10.3%

EPS成長率

Life Sciences 収益成長	0%
収益成長率	5.5%
将来の株主資本利益率	32.2%
アナリストカバレッジ	Good
最終更新日	19 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BMV:WAT * - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	3,301	760	743	922	14
12/31/2025	3,112	712	762	914	18
12/31/2024	2,943	630	647	769	17
9/28/2024	2,905	623	620	752	N/A
6/29/2024	2,877	596	561	705	N/A
3/30/2024	2,909	604	514	669	N/A
12/31/2023	2,956	642	442	603	N/A
9/30/2023	2,995	653	390	571	N/A
7/1/2023	2,992	675	387	572	N/A
4/1/2023	2,966	689	425	610	N/A
12/31/2022	2,972	708	428	612	N/A
10/1/2022	2,950	697	465	631	N/A
7/2/2022	2,901	702	477	641	N/A
4/2/2022	2,868	705	565	727	N/A
12/31/2021	2,786	693	579	747	N/A
10/2/2021	2,736	695	626	797	N/A
7/3/2021	2,671	660	642	802	N/A
4/3/2021	2,509	616	697	857	N/A
12/31/2020	2,365	522	618	791	N/A
9/26/2020	2,295	504	536	715	N/A
6/27/2020	2,278	515	495	691	N/A
3/28/2020	2,358	537	430	619	N/A
12/31/2019	2,407	592	479	643	N/A
9/28/2019	2,405	577	491	633	N/A
6/29/2019	2,406	580	475	631	N/A
3/30/2019	2,403	591	467	604	N/A
12/31/2018	2,420	594	508	604	N/A
9/29/2018	2,392	55	489	615	N/A
6/30/2018	2,380	51	N/A	623	N/A
3/31/2018	2,342	27	N/A	699	N/A
12/31/2017	2,309	20	N/A	698	N/A
9/30/2017	2,251	548	N/A	679	N/A
7/1/2017	2,212	537	N/A	674	N/A
4/1/2017	2,190	533	N/A	656	N/A
12/31/2016	2,167	522	N/A	643	N/A
10/1/2016	2,125	498	N/A	623	N/A
7/2/2016	2,099	490	N/A	613	N/A
4/2/2016	2,057	467	N/A	567	N/A
12/31/2015	2,042	469	N/A	573	N/A
10/3/2015	2,040	469	N/A	568	N/A
7/4/2015	2,032	467	N/A	557	N/A
4/4/2015	2,019	457	N/A	550	N/A
12/31/2014	1,989	432	N/A	512	N/A
9/27/2014	1,971	422	N/A	493	N/A
6/28/2014	1,935	406	N/A	470	N/A
3/29/2014	1,904	399	N/A	473	N/A
12/31/2013	1,904	450	N/A	485	N/A

アナリストによる今後の成長予測

収入対貯蓄率: WAT *の予測収益成長率 (年間8.6% ) は貯蓄率 ( 8.1% ) を上回っています。

収益対市場: WAT *の収益 ( 8.6% ) MX市場 ( 11.4% ) よりも低い成長が予測されています。

高成長収益: WAT *の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: WAT *の収益 ( 5.5% ) MX市場 ( 7.2% ) よりも低い成長が予測されています。

高い収益成長: WAT *の収益 ( 5.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: WAT *の自己資本利益率は、3年後には高くなると予測されています ( 32.2 %)

Waters 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Waters Corporation Raises Earnings Guidance for the Full Year of Fiscal Year Ending December 31, 2024

Waters Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Waters Corporation Provides Earnings Guidance for the First Quarter and Full-Year 2024

Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2023

Waters Corporation Provides Earnings Guidance for the Second Quarter of 2023 and Fiscal Year 2023

Waters Corporation Provides Earnings Guidance for the First Quarter of 2023 and Fiscal Year 2023

Recent updates

Investor sentiment improves as stock rises 17%

Waters Corporation Raises Earnings Guidance for the Full Year of Fiscal Year Ending December 31, 2024

Waters Corporation Announces New Bioseparations Tools Accelerate and Improve Development of Rna-Based Vaccines and Therapies Using LC-MS Analysis

Waters Corporation Introduces TA Instruments Discovery Core Rheometer

Second quarter 2024 earnings released: EPS: US$2.41 (vs US$2.56 in 2Q 2023)

Waters Corporation to Report Q2, 2024 Results on Jul 31, 2024

Waters Corporation New Rapid Screening-DSC Enables Up to 24x Faster Thermal Stability Testing at Ultra-Low Sample Volumes for Antibody Drugs

Independent Director recently bought Mex$5.6m worth of stock

First quarter 2024 earnings released: EPS: US$1.73 (vs US$2.39 in 1Q 2023)

Waters Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Waters Corporation Accelerates the Development of Gene-Based Therapeutics with New GTxResolve Premier SEC Columns

Waters Corporation, Annual General Meeting, May 23, 2024

Independent Director recently sold Mex$3.0m worth of stock

Full year 2023 earnings released: EPS: US$10.87 (vs US$11.80 in FY 2022)

Waters Corporation Provides Earnings Guidance for the First Quarter and Full-Year 2024

High number of new directors

Third quarter 2023 earnings released: EPS: US$2.28 (vs US$2.61 in 3Q 2022)

High number of new directors

Waters Corporation Announces Resignation of Jonathan Pratt as Senior Vice President of the Waters Division

Waters Corporation Launched OligoWorks SPE Workflow and Kits

High number of new directors

Waters Corporation Introduces DynaPro™? ZetaStar™? Instrument from its Wyatt Technology™? Portfolio for Nanoparticle Analysis

Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2023

Waters Corporation Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications

High number of new directors

Waters Corporation Boosts Resolution and Triples Scan Speed of Select Series MRT for Metabolomics and MS Imaging

Waters Corporation Provides Earnings Guidance for the Second Quarter of 2023 and Fiscal Year 2023

High number of new directors

High number of new directors

Independent Director recently bought Mex$18m worth of stock

High number of new directors

Waters Corporation Provides Earnings Guidance for the First Quarter of 2023 and Fiscal Year 2023

High number of new directors

Waters Corporation Announces Waters_Connect™ System Monitoring

Waters Corporation Announces Executive Changes

Waters Corporation Appoints Dan Brennan and Mark Vergnano to Board of Directors

Waters Introduces New PFAS Quantitation Workflow Enabled by Enhancements to Waters_Connect Informatics Platform

Waters Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

Waters Automates Solid Phase Extraction of Biological, Food and Environmental Samples with Andrew+ Pipetting Robot

Waters Extends Capabilities of Flagship Ta Instruments Rheometer for Efficient and Repeatable Powder Analysis

Second quarter 2022 earnings released: EPS: US$2.74 (vs US$2.71 in 2Q 2021)

Waters Corporation Provides Earnings Guidance for the Third Quarter Ending October 1, 2022 and Full Year Ending December 31, 2022

Waters Corporation to Report Q2, 2022 Results on Aug 02, 2022

Waters Corporation(NYSE:WAT) dropped from Russell 1000 Value-Defensive Index

Waters Corporation Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development

Waters Corporation Provides Earnings Guidance for the Quarter Ending July 2, 2022 and Full Year Ending December 31, 2022

Waters Corporation, Annual General Meeting, May 24, 2022

Waters Corporation Announces Resignation of John Ballbach from the Board of Directors

Waters Introduces Xevo TQ Absolute

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Waters Corporation Provides Earnings Guidance for the First Quarter Ending April 2, 2022 and Year Ending December 31, 2022

High number of new directors

Third quarter 2021 earnings released: EPS US$2.63 (vs US$2.05 in 3Q 2020)

High number of new directors

Independent Director Michael Berendt has left the company

Waters Corporation Introduces the Waters™ BioAccord™ System

Independent Director recently sold Mex$24m worth of stock

High number of new directors

Investor sentiment improved over the past week

Lead Independent Director recently sold Mex$67m worth of stock

Second quarter 2021 earnings released: EPS US$2.71 (vs US$1.99 in 2Q 2020)

High number of new directors

Waters Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2021

Waters Corporation Introduces TRIOS AutoPilot Software

Waters Corp. Introduces the Waters Arc Premier System

Waters Corporation Introduces the Sars-Cov-2 Lc-Ms Kit (Ruo) to Advance Clinical Research of Infectious Diseases

First quarter 2021 earnings released: EPS US$2.38 (vs US$0.86 in 1Q 2020)

Waters Corporation Provides Earnings Guidance for the Three Months Ended July 3, 2021 and for the Full Year Ended December 31, 2021

Waters Corporation Introduces A New Peptide Multi-Attribute Method Workflow for the Waters BioAccord LC-MS System